Navigation Links
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
Date:9/5/2012

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. R333 is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus erythematosus (DLE, or lupus of the skin). 

"R343 and R333 are leading the way in a substantial lineup of proprietary product candidates in Rigel's pipeline," said James M. Gower, chairman and chief executive officer of Rigel.  "In addition to fostamatinib, which is in Phase 3 with our partner AstraZeneca, we now have two products in Phase 2 clinical studies and several more in, or preparing to enter, the clinic. Rigel continues to demonstrate its R&D productivity," he added.

Phase 2 Study of R343, an inhaled SYK inhibitor
Approximately 270 adults with allergic asthma will be randomized into the three arms of this Phase 2 clinical study of R343, called SITAR (SYK Inhibition for Treatment of Asthma with R343), for eight weeks of treatment with either of two different doses of the study agent or placebo. The primary endpoint of this double-blind, multi-center study will be the measurement of each patient's change in FEV1 (the maximum amount of air a person can forcefully exhale in one second) from baseline to dosing completion.  Rigel will be using the 3M™ Taper Dry Powder Inhaler device for this trial. Rigel expects to complete this study in 2013.

Phase 2 Study of R333, a topical JAK/SYK inhibitor
In this Phase 2, double-blind, multi-center study, called SKINDLE (SYK Kinase Inhibition for DLE), more than 50 patients with active discoid skin lesions from DLE or Systemic Lupus Eryth
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... 2014 Recently, iFitDress.com, one of the most ... one shoulder evening gown collection. According to the ... at discounted rates (up to 69% off) at present. Additionally, ... , “I am a frequent caller of your site. ... my dress, I feel quite happy. All items are of ...
(Date:9/16/2014)... 16, 2014 The second federal bellwether ... & Johnson subsidiary Ethicon concluded with the jury in ... and awarding her $3.27 million in damages, according to ... report, “jurors found Ethicon liable for selling faulty devices ... users were at risk from side effects that include ...
(Date:9/16/2014)... forensic techniques are shedding light on a 500-year-old mystery: ... the last English monarch to die in battle? ... whole-body CT scans and micro-CT imaging of injured bones, ... suffered at the Battle of Bosworth Field, where he ... revealed that two skull injuries could have killed the ...
(Date:9/16/2014)... Paradigm Physical Therapy is proud to ... treatment for their patients. Dry needling is a procedure ... of musculoskeletal problems. , In this invasive procedure, a ... skin and muscle to create a trigger point. Using ... helps to deactivate and release the trigger point within ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Paradigm Physical Therapy Introduces Dry Needling 2
... cells (CTCs) may be a promising alternative, noninvasive source ... presented at the Fourth AACR International Conference on Molecular ... idea is that CTCs can provide real-time information about ... biopsy," said Siminder Kaur Atwal, Ph.D., senior research associate ...
... study carried out by Spanish researchers has shown that the ... for good or for bad, the way in which work-related ... manifests itself. Noise-related hearing loss is the most common occupational ... presence of metalworking fluids exhibit a delay in hearing alteration ...
... TUESDAY, Sept. 28 (HealthDay News) -- American middle-school students who ... mentally better off than those who don,t, a new study ... explore the potential health impact that team sports activity might ... ages of 12 and 14. "Other studies have looked ...
... By Steven Reinberg HealthDay Reporter , ... comparison of drug-coated stents -- the metal mesh tubes ... model using the drug sirolimus came out on top, ... coated with zotarolimus, fell short, the study found. ...
... discernible influence on how African American patients with asthma ... study. Researchers found that improved lung function in ... series of baseline breathing function measures, not genetic ancestry. ... of Allergy & Clinical Immunology , http://www.aaaai.org/media/jaci/ ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... Pediatrics doesn,t want children exposed to tobacco ads at ... marketing and advertisements for erectile dysfunction drugs and other ... of the recommendations in its new policy statement, "Children, ...
Cached Medicine News:Health News:Circulating tumor cells can provide 'real-time' information on patient's current disease state 2Health News:Noise and chemicals: Workers are losing their hearing 2Health News:Team Sports Pep Up Middle-School Kids 2Health News:Team Sports Pep Up Middle-School Kids 3Health News:In Test of Stents, Old Standby Wins Out 2Health News:No link between genetic ancestry, asthma response in African-Americans 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 3
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: